ClinicalTrials.gg
CompletedNCT01691560Updated May 29, 2014Results posted

Exploratory Study to Evaluate an Occlusion Based Dentifrice in Relief of Dentinal Hypersensitivity

A Phase 2 interventional study of 5% calcium sodium phosphosilicate/ sodium monofluorophosphate dentifrice and 0% calcium sodium phosphosilicate/sodium monofluorophosphate dentifrice in Dentine Hypersensitivity, sponsored by GlaxoSmithKline. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2014-05-29.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies in Dentin Sensitivity by GlaxoSmithKline — none open to participants now, none under way, none of them phase 3. Dentin Sensitivity · GlaxoSmithKline.

Enrollment
16th of 28
140 · median 164
Started
2012
with 3 others
Phase 2
6 of 28
none open now
Registered
5th of 28
by date

Among the 28 studies in Dentin Sensitivity by GlaxoSmithKline, this one is the 16th largest by enrollment, is one of 4 that started in 2012, is one of 6 in phase 2, and was the 5th registered.

Dentin Sensitivity

290 studies on the registry are indexed under Dentin Sensitivity; 48 are open to participants now.

Browse Dentin Sensitivity studies →

Open to participants now

None of the 28 studies in Dentin Sensitivity by GlaxoSmithKline is open now. The open studies under Dentin Sensitivity, anywhere →

Who these studies take

Of the 19 Dentin Sensitivity studies recruiting now, 6 (32%) set no upper age limit and 12 (63%) stop at 75 or younger; 1 takes children under 18; 11 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 28 studies in Dentin Sensitivity by GlaxoSmithKline as a file.
02

Study summary

The purpose of this exploratory study is to compare the treatment effect on dentinal hypersensitivity of a tubule occluding dentifrice as measured by Schiff and Tactile sensitivity. This proof of concept study will compare the test dentifrice with three other treatment groups.

Read the detailed description

This will be a single center, eight week, randomized, controlled, examiner blind, four treatment arm, parallel design, stratified (by maximum baseline Schiff Sensitivity Score of the two selected test teeth), exploratory study in participants with at least two sensitive teeth that meet all the criteria at the Screening and Baseline visit. Participants will be assessed at Baseline, four and eight weeks to monitor clinical efficacy and safety.

03

Conditions studied

  • Dentine Hypersensitivity

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants between 18 and 55 years of age, in good general health, with pre-existing self-reported and clinically diagnosed tooth sensitivity are required for entry into the study
  2. Participants will be required to have at least four teeth with facial/cervical erosion, abrasion and/or gingival recession which respond to qualifying evaporative (air) assessment at the Screening visit and have at least two teeth (incisors, canines or pre-molars) demonstrating signs of sensitivity, measured by qualifying tactile threshold (Yeaple ≤ 20 gram (g)) and evaporative (air) (Schiff Sensitivity Score ≥ 2) assessments at the Baseline visit

Exclusion criteria

Exclusion Criteria:

  1. Pregnancy: Women who are known to be pregnant or who are intending to become pregnant over the duration of the study.
  2. Breast-feeding: Women who are breast-feeding.
  3. Medical History: a) Chronic debilitating disease is present b) Chronic disease or other condition is present that is associated with intermittent episodes or constant daily pain, such as arthritis, low back pain, dysmenorrhea, etc.
  4. Medications: Daily doses of medication, which in the opinion of the investigator, might interfere with the perception of pain, are being taken. Examples of such medications include analgesics, anticonvulsants, antihistamines that cause marked or moderate sedation, sedatives, tranquilizers, mood-altering and anti-inflammatory drugs.
  5. Dentition Exclusions: a) Sensitive teeth not expected to respond to treatment with an over-the- counter dentifrice in the opinion of the investigator. b) Teeth with exposed dentine but with deep, defective or facial restorations, teeth used as abutments for fixed or removable partial dentures, teeth with full crowns, orthodontic bands, extensive caries or cracked enamel. Sensitive teeth with contributing etiologies other than erosion, abrasion or recession of exposed dentine. c) Dental professional hygiene (includes dental prophylaxis, irrigation, and intensive anti-microbial/anti-biotic therapy) within 14 days of the screening visit. d) Presence of dental implants. e) Lip or tongue piercings. f) Periodontal surgical history within the past 6 months or have been scaled /root planed within the past 3 months.
  6. Allergy/Intolerance: Known or suspected intolerance or to the study materials (or closely related compounds) or any of their stated ingredients.
  7. Clinical Study/Experimental Medication: a) Participation in another clinical study or receipt of an drug within 30 days of the screening visit b) Previous participation in this study.
  8. Other: Any subject who in the opinion of the investigator, should not participate in the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
140 participants (actual)

Study arms

  • Experimental
    5% calcium sodium phosphosilicate/sodium monofluorophosphate

    Dentifrice containing 5.0% w/w calcium sodium phosphosilicate with sodium monofluorophosphate containing 1500 parts per million fluoride (ppmF).

    Drug: 5% calcium sodium phosphosilicate/ sodium monofluorophosphate dentifrice

  • Active comparator
    0% calcium sodium phosphosilicate/sodium monofluorophosphate

    Dentifrice containing 0% w/w calcium sodium phosphosilicate and 1500ppmF as sodium monofluorophosphate

    Drug: 0% calcium sodium phosphosilicate/sodium monofluorophosphate dentifrice

  • Active comparator
    Sodium monofluorophosphate

    Dentifrice containing 1000 ppmF as sodium monofluorophosphate

    Drug: Sodium monofluorophosphate dentifrice

  • Active comparator
    Sodium fluoride

    Dentifrice containing 1100 ppmF as sodium fluoride

    Drug: Sodium fluoride dentifrice

Interventions

  • Drug5% calcium sodium phosphosilicate/ sodium monofluorophosphate dentifrice

    Dentifrice containing 5.0% w/w calcium sodium phosphosilicate and 1500ppmF as sodium monofluorophosphate

  • Drug0% calcium sodium phosphosilicate/sodium monofluorophosphate dentifrice

    Dentifrice containing 0% w/w calcium sodium phosphosilicate and 1500ppmF as sodium monofluorophosphate

  • Dentifrice containing 1000 ppmF as sodium monofluorophosphate

  • Dentifrice containing 1100 ppmF as sodium fluoride

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Evaporative Air Sensitivity Pain Response on Schiff Sensitivity Scale at Week 4

    Response to a constant jet of air applied to hypersensitive teeth was evaluated using a Schiff Sensitivity pain response scale. According to this analog scale, pain response for each individual stimulated tooth ranged from 0 to 3; 0 - participant does not respond to air stimulation, 1 - participant responds to air stimulus but does not request discontinuation of stimulus, 2 - participant responds to air stimulus and request discontinuation of stimulus, 3 - participant responds to air stimulus, considers stimulus to be painful and request discontinuation of stimulus.

    Time frame: Baseline to 4 weeks post administration of study treatment

  2. Change From Baseline in Tactile Sensitivity Pain Response (g) at Week 4

    Response to increasing force on hypersensitive teeth was evaluated using a Yeaple Probe pain response scale. In tactile sensitivity assessment, an increasing force is applied to hypersensitive tooth until a yes response was recorded or the maximum force was reached.

    Time frame: Baseline to 4 weeks post administration of study treatment

  3. Change From Baseline in Evaporative Air Sensitivity Pain Response on Schiff Sensitivity Scale at Week 8

    Response to a constant jet of air applied to hypersensitive teeth was evaluated using a Schiff Sensitivity pain response scale. According to this analog scale, pain response for each individual stimulated tooth ranged from 0 to 3; 0 - participant does not respond to air stimulation, 1 - participant responds to air stimulus but does not request discontinuation of stimulus, 2 - participant responds to air stimulus and request discontinuation of stimulus, 3 - participant responds to air stimulus, considers stimulus to be painful and request discontinuation of stimulus.

    Time frame: Baseline to 8 weeks post administration of study treatment

  4. Change From Baseline in Tactile Sensitivity Pain Response (g) at Week 8

    Response to increasing force on hypersensitive teeth was evaluated using a Yeaple Probe pain response scale. In tactile sensitivity assessment, an increasing force is applied to hypersensitive tooth until a yes response was recorded or the maximum force was reached.

    Time frame: Baseline to 8 weeks post administration of study treatment

  5. Change From Baseline in Evaporative Air Sensitivity Response on a Visual Rating Scale (VRS) at Week 4

    Participants rated the intensity of their response to the stimulus using a 10 point Visual rating scale of 1 (no Pain) to 10 (intense pain).

    Time frame: Baseline to 4 weeks post administration of study treatment

  6. Change From Baseline in Evaporative Air Sensitivity Response on VRS at Week 8

    Participants rated the intensity of their response to the stimulus using a 10 point VRS of 1 (no Pain) to 10 (intense pain).

    Time frame: Baseline to 8 weeks post administration of study treatment

07

Results

Posted May 29, 2014

Participant flow

Participants were recruited at the clinical site.

Participant flow — Overall Study
Milestone5% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate0% Calcium Sodium Phosphosilicate/ Sodium MonofluorophosphateSodium MonofluorophosphateSodium Fluoride
Started34333433
Completed34333433
Not completed0000

Outcome measures

PrimaryChange From Baseline in Evaporative Air Sensitivity Pain Response on Schiff Sensitivity Scale at Week 4

Response to a constant jet of air applied to hypersensitive teeth was evaluated using a Schiff Sensitivity pain response scale. According to this analog scale, pain response for each individual stimulated tooth ranged from 0 to 3; 0 - participant does not respond to air stimulation, 1 - participant responds to air stimulus but does not request discontinuation of stimulus, 2 - participant responds to air stimulus and request discontinuation of stimulus, 3 - participant responds to air stimulus, considers stimulus to be painful and request discontinuation of stimulus.

Time frame:
Baseline to 4 weeks post administration of study treatment
Reported as:
Least squares mean · Score on a scale
Change From Baseline in Evaporative Air Sensitivity Pain Response on Schiff Sensitivity Scale at Week 4
Score on a scale5% Calcium Sodium Phosphosilicate/ Sodium MonofluorophosphateSodium MonofluorophosphateSodium Fluoride0% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate
Change From Baseline in Evaporative Air Sensitivity Pain Response on Schiff Sensitivity Scale at Week 4-0.36 (-0.53 to -0.20)-0.43 (-0.59 to -0.27)-0.40 (-0.57 to -0.23)-0.45 (-0.62 to -0.28)
Statistical analysis
  • 5% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate vs 0% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate · ANCOVA · p = 0.4553 · Adjusted mean difference: 0.09 · 95% CI -0.14 to 0.32Difference is First named treatment minus Second named treatment that negative difference implies the mean of the second named treatment is larger than that of the first named treatment.
  • 5% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate vs Sodium Monofluorophosphate · ANCOVA · p = 0.5689 · Adjusted mean difference: 0.07 · 95% CI -0.16 to 0.30Difference is First named treatment minus Second named treatment that negative difference implies the mean of the second named treatment is larger than that of the first named treatment.
  • 5% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate vs Sodium Fluoride · ANCOVA · p = 0.7517 · Adjusted mean difference: 0.04 · 95% CI -0.20 to 0.27Difference is First named treatment minus Second named treatment that negative difference implies the mean of the second named treatment is larger than that of the first named treatment.
  • Sodium Monofluorophosphate vs 0% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate · ANCOVA · p = 0.8549 · Adjusted mean difference: 0.02 · 95% CI -0.21 to 0.25Difference is First named treatment minus Second named treatment that negative difference implies the mean of the second named treatment is larger than that of the first named treatment.
  • Sodium Fluoride vs 0% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate · ANCOVA · p = 0.6685 · Adjusted mean difference: 0.05 · 95% CI -0.18 to 0.29Difference is First named treatment minus Second named treatment that negative difference implies the mean of the second named treatment is larger than that of the first named treatment.
  • Sodium Monofluorophosphate vs Sodium Fluoride · ANCOVA · p = 0.8031 · Adjusted mean difference: -0.03 · 95% CI -0.26 to 0.20Difference is First named treatment minus Second named treatment that negative difference implies the mean of the second named treatment is larger than that of the first named treatment.
PrimaryChange From Baseline in Tactile Sensitivity Pain Response (g) at Week 4

Response to increasing force on hypersensitive teeth was evaluated using a Yeaple Probe pain response scale. In tactile sensitivity assessment, an increasing force is applied to hypersensitive tooth until a yes response was recorded or the maximum force was reached.

Time frame:
Baseline to 4 weeks post administration of study treatment
Reported as:
Mean · grams
Change From Baseline in Tactile Sensitivity Pain Response (g) at Week 4
grams5% Calcium Sodium Phosphosilicate/ Sodium MonofluorophosphateSodium MonofluorophosphateSodium Fluoride0% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate
Change From Baseline in Tactile Sensitivity Pain Response (g) at Week 47.31 ± 11.2276.32 ± 13.0454.09 ± 4.7523.64 ± 6.030
Statistical analysis
  • 5% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate vs 0% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate · Wilcoxon (Mann-Whitney) · p = 0.0467 · Median difference (final values): 0 · 95% CI 0 to 5Difference is First named treatment minus Second named treatment such that a positive difference favors the first named treatment.
  • 5% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate vs Sodium Monofluorophosphate · Wilcoxon (Mann-Whitney) · p = 0.1133 · Median difference (final values): 0 · 95% CI 0 to 5Difference is First named treatment minus Second named treatment such that a positive difference favors the first named treatment.
  • 5% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate vs Sodium Fluoride · Wilcoxon (Mann-Whitney) · p = 0.2579 · Median difference (final values): 0 · 95% CI 0 to 5Difference is First named treatment minus Second named treatment such that a positive difference favors the first named treatment.
  • Sodium Monofluorophosphate vs 0% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate · Wilcoxon (Mann-Whitney) · p = 0.6149 · Median difference (final values): 0 · 95% CI 0 to 0Difference is First named treatment minus Second named treatment such that a positive difference favors the first named treatment.
  • Sodium Fluoride vs 0% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate · Wilcoxon (Mann-Whitney) · p = 0.3259 · Median difference (final values): 0 · 95% CI 0 to 5Difference is First named treatment minus Second named treatment such that a positive difference favors the first named treatment.
  • Sodium Monofluorophosphate vs Sodium Fluoride · Wilcoxon (Mann-Whitney) · p = 0.5721 · Median difference (final values): 0 · 95% CI 0 to 0Difference is First named treatment minus Second named treatment such that a positive difference favors the first named treatment.
PrimaryChange From Baseline in Evaporative Air Sensitivity Pain Response on Schiff Sensitivity Scale at Week 8

Response to a constant jet of air applied to hypersensitive teeth was evaluated using a Schiff Sensitivity pain response scale. According to this analog scale, pain response for each individual stimulated tooth ranged from 0 to 3; 0 - participant does not respond to air stimulation, 1 - participant responds to air stimulus but does not request discontinuation of stimulus, 2 - participant responds to air stimulus and request discontinuation of stimulus, 3 - participant responds to air stimulus, considers stimulus to be painful and request discontinuation of stimulus.

Time frame:
Baseline to 8 weeks post administration of study treatment
Reported as:
Least squares mean · Score on a scale
Change From Baseline in Evaporative Air Sensitivity Pain Response on Schiff Sensitivity Scale at Week 8
Score on a scale5% Calcium Sodium Phosphosilicate/ Sodium MonofluorophosphateSodium MonofluorophosphateSodium Fluoride0% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate
Change From Baseline in Evaporative Air Sensitivity Pain Response on Schiff Sensitivity Scale at Week 8-0.55 (-0.78 to -0.33)-0.43 (-0.66 to -0.20)-0.43 (-0.66 to -0.20)-0.92 (-1.15 to -0.68)
Statistical analysis
  • 5% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate vs 0% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate · ANCOVA · p = 0.0292 · Adjusted mean difference: 0.36 · 95% CI 0.04 to 0.69Difference is First named treatment minus Second named treatment that negative difference implies the mean of the second named treatment is larger than that of the first named treatment.
  • 5% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate vs Sodium Monofluorophosphate · ANCOVA · p = 0.4484 · Adjusted mean difference: -0.12 · 95% CI -0.44 to 0.20Difference is First named treatment minus Second named treatment that negative difference implies the mean of the second named treatment is larger than that of the first named treatment.
  • 5% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate vs Sodium Fluoride · ANCOVA · p = 0.4537 · Adjusted mean difference: -0.12 · 95% CI -0.45 to 0.20Difference is First named treatment minus Second named treatment that negative difference implies the mean of the second named treatment is larger than that of the first named treatment.
  • Sodium Monofluorophosphate vs 0% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate · ANCOVA · p = 0.0037 · Adjusted mean difference: 0.49 · 95% CI 0.16 to 0.81Difference is First named treatment minus Second named treatment that negative difference implies the mean of the second named treatment is larger than that of the first named treatment.
  • Sodium Fluoride vs 0% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate · ANCOVA · p = 0.0040 · Adjusted mean difference: 0.48 · 95% CI 0.16 to 0.81Treatment as fixed factor, baseline Schiff score as covariate. Difference is First named treatment minus Second named treatment that negative difference implies the mean of the second named treatment is larger than that of the first named treatment.
  • Sodium Monofluorophosphate vs Sodium Fluoride · ANCOVA · p = 0.9974 · Adjusted mean difference: 0.00 · 95% CI -0.32 to 0.32Difference is First named treatment minus Second named treatment that negative difference implies the mean of the second named treatment is larger than that of the first named treatment.
PrimaryChange From Baseline in Tactile Sensitivity Pain Response (g) at Week 8

Response to increasing force on hypersensitive teeth was evaluated using a Yeaple Probe pain response scale. In tactile sensitivity assessment, an increasing force is applied to hypersensitive tooth until a yes response was recorded or the maximum force was reached.

Time frame:
Baseline to 8 weeks post administration of study treatment
Reported as:
Mean · grams
Change From Baseline in Tactile Sensitivity Pain Response (g) at Week 8
grams5% Calcium Sodium Phosphosilicate/ Sodium MonofluorophosphateSodium MonofluorophosphateSodium Fluoride0% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate
Change From Baseline in Tactile Sensitivity Pain Response (g) at Week 810.15 ± 15.1005.88 ± 11.5124.39 ± 5.55611.97 ± 16.486
Statistical analysis
  • 5% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate vs 0% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate · Wilcoxon (Mann-Whitney) · p = 0.8861 · Median difference (final values): 0 · 95% CI -5 to 5Difference is First named treatment minus Second named treatment such that a positive difference favors the first named treatment.
  • 5% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate vs Sodium Monofluorophosphate · Wilcoxon (Mann-Whitney) · p = 0.0641 · Median difference (final values): 0 · 95% CI 0 to 5Difference is First named treatment minus Second named treatment such that a positive difference favors the first named treatment.
  • 5% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate vs Sodium Fluoride · Wilcoxon (Mann-Whitney) · p = 0.1831 · Median difference (final values): 0 · 95% CI 0 to 5Difference is First named treatment minus Second named treatment such that a positive difference favors the first named treatment.
  • Sodium Monofluorophosphate vs 0% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate · Wilcoxon (Mann-Whitney) · p = 0.0871 · Median difference (final values): 0 · 95% CI -10 to 0Difference is First named treatment minus Second named treatment such that a positive difference favors the first named treatment.
  • Sodium Fluoride vs 0% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate · Wilcoxon (Mann-Whitney) · p = 0.1690 · Median difference (final values): 0 · 95% CI -10 to 0Difference is First named treatment minus Second named treatment such that a positive difference favors the first named treatment.
  • Sodium Monofluorophosphate vs Sodium Fluoride · Wilcoxon (Mann-Whitney) · p = 0.3829 · Median difference (final values): 0 · 95% CI -5 to 0Difference is First named treatment minus Second named treatment such that a positive difference favors the first named treatment.
PrimaryChange From Baseline in Evaporative Air Sensitivity Response on a Visual Rating Scale (VRS) at Week 4

Participants rated the intensity of their response to the stimulus using a 10 point Visual rating scale of 1 (no Pain) to 10 (intense pain).

Time frame:
Baseline to 4 weeks post administration of study treatment
Reported as:
Least squares mean · Score on a scale
Change From Baseline in Evaporative Air Sensitivity Response on a Visual Rating Scale (VRS) at Week 4
Score on a scale5% Calcium Sodium Phosphosilicate/ Sodium MonofluorophosphateSodium MonofluorophosphateSodium Fluoride0% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate
Change From Baseline in Evaporative Air Sensitivity Response on a Visual Rating Scale (VRS) at Week 4-1.22 (-1.76 to -0.69)-1.07 (-1.60 to -0.55)-1.35 (-1.89 to -0.81)-1.25 (-1.80 to -0.71)
Statistical analysis
  • 5% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate vs 0% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate · ANCOVA · p = 0.9421 · Adjusted mean difference: 0.03 · 95% CI -0.74 to 0.80Difference is first named treatment minus second named treatment that a negative difference implies the mean of second named treatment is larger than that of the first named treatment.
  • 5% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate vs Sodium Monofluorophosphate · ANCOVA · p = 0.6918 · Adjusted mean difference: -0.15 · 95% CI -0.90 to 0.60Difference is first named treatment minus second named treatment that a negative difference implies the mean of second named treatment is larger than that of the first named treatment.
  • 5% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate vs Sodium Fluoride · ANCOVA · p = 0.7421 · Adjusted mean difference: 0.13 · 95% CI -0.63 to 0.88Difference is first named treatment minus second named treatment that a negative difference implies the mean of second named treatment is larger than that of the first named treatment.
  • Sodium Monofluorophosphate vs 0% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate · ANCOVA · p = 0.6433 · Adjusted mean difference: 0.18 · 95% CI -0.58 to 0.94Difference is first named treatment minus second named treatment that a negative difference implies the mean of second named treatment is larger than that of the first named treatment.
  • Sodium Fluoride vs 0% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate · ANCOVA · p = 0.8010 · Adjusted mean difference: -0.10 · 95% CI -0.86 to 0.67Difference is first named treatment minus second named treatment that a negative difference implies the mean of second named treatment is larger than that of the first named treatment.
  • Sodium Monofluorophosphate vs Sodium Fluoride · ANCOVA · p = 0.4692 · Adjusted mean difference: 0.28 · 95% CI -0.48 to 1.03Difference is first named treatment minus second named treatment that a negative difference implies the mean of second named treatment is larger than that of the first named treatment.
PrimaryChange From Baseline in Evaporative Air Sensitivity Response on VRS at Week 8

Participants rated the intensity of their response to the stimulus using a 10 point VRS of 1 (no Pain) to 10 (intense pain).

Time frame:
Baseline to 8 weeks post administration of study treatment
Reported as:
Least squares mean · Score on a scale
Change From Baseline in Evaporative Air Sensitivity Response on VRS at Week 8
Score on a scale5% Calcium Sodium Phosphosilicate/ Sodium MonofluorophosphateSodium MonofluorophosphateSodium Fluoride0% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate
Change From Baseline in Evaporative Air Sensitivity Response on VRS at Week 8-1.76 (-2.35 to -1.17)-1.22 (-1.81 to -0.63)-1.31 (-1.90 to -0.71)-2.06 (-2.67 to -1.46)
Statistical analysis
  • 5% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate vs 0% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate · ANCOVA · p = 0.4797 · Adjusted mean difference: 0.31 · 95% CI -0.55 to 1.16Difference is first named treatment minus second named treatment that a negative difference implies the mean of second named treatment is larger than that of the first named treatment.
  • 5% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate vs Sodium Monofluorophosphate · ANCOVA · p = 0.2023 · Adjusted mean difference: -0.54 · 95% CI -1.37 to 0.29Difference is first named treatment minus second named treatment that a negative difference implies the mean of second named treatment is larger than that of the first named treatment.
  • 5% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate vs Sodium Fluoride · ANCOVA · p = 0.2917 · Adjusted mean difference: -0.45 · 95% CI -1.29 to 0.39Difference is first named treatment minus second named treatment that a negative difference implies the mean of second named treatment is larger than that of the first named treatment.
  • Sodium Monofluorophosphate vs 0% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate · ANCOVA · p = 0.0503 · Adjusted mean difference: 0.85 · 95% CI 0.00 to 1.69Difference is first named treatment minus second named treatment that a negative difference implies the mean of second named treatment is larger than that of the first named treatment.
  • Sodium Fluoride vs 0% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate · ANCOVA · p = 0.0811 · Adjusted mean difference: 0.76 · 95% CI -0.09 to 1.61Difference is first named treatment minus second named treatment that a negative difference implies the mean of second named treatment is larger than that of the first named treatment.
  • Sodium Monofluorophosphate vs Sodium Fluoride · ANCOVA · p = 0.8322 · Adjusted mean difference: 0.09 · 95% CI -0.75 to 0.93Difference is first named treatment minus second named treatment that a negative difference implies the mean of second named treatment is larger than that of the first named treatment.

Adverse events

Collected over Adverse events were collected collected from the start of the investigational product (or washout product), and until 5 days following last administration of the investigational product.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
5% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate—0/34 (0%)0/34 (0%)
0% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate—0/33 (0%)0/33 (0%)
Sodium Monofluorophosphate—0/34 (0%)0/34 (0%)
Sodium Fluoride—0/33 (0%)0/33 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(Years)5% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate0% Calcium Sodium Phosphosilicate/ Sodium MonofluorophosphateSodium MonofluorophosphateSodium FluorideTotal
Mean35.4 ± 10.4533.2 ± 10.1338.2 ± 8.8836.2 ± 9.6235.8 ± 9.85
Sex: Female, Male
Sex: Female, Male(Participants)5% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate0% Calcium Sodium Phosphosilicate/ Sodium MonofluorophosphateSodium MonofluorophosphateSodium FluorideTotal
Female2524272298
Male9971136
08

Study locations

1 site
  • BioSci Research America
    Las Vegas, Nevada 89121-5466, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2012, a primary completion of Nov 2012 and a completion of Nov 2012. It does not say whether these dates are actual or estimated.

Results were first posted in May 2014, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 20, 2012
First posted
Sep 24, 2012
Start
Aug 2012
Primary completionActual
Nov 2012
CompletionActual
Nov 2012
Results first posted
May 29, 2014
Last update
May 29, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01691560
Lead sponsor
GlaxoSmithKline
Collaborators
BioSci Research
Responsible party
Sponsor
First posted
Sep 24, 2012
Start date
Aug 2012
Primary completion
Nov 2012
Completion
Nov 2012
Results posted
May 29, 2014
Last update
May 29, 2014

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion